Marijuana Studies and

Cannabis Research

09/28/2018
Author(s): F. J. Bermúdez-Silva & J. Suárez & E. Baixeras & N. Cobo & D. Bautista & A. L. Cuesta-Muñoz & E. Fuentes & P. Juan-Pico & M. J. Castro & G. Milman & R. Mechoulam & A. Nadal & F. Rodríguez de Fonseca. The stimulation with CB1 was able to increase the secretion of insulin and glucagon, as well as the lipogenesis in the liver and adipose tissue, blocking the incorporation of glucose in the muscle cells, which led to a “saving cycle”: lower expenditure energy and greater energy storage. The improved release of insulin can help facilitate the incorporation of glucose into the adipocytes, while the improved release of glucagon can maintain high levels of plasma glucose, which favors this “saving cycle”. Under this hypothesis, CB1 can be considered a new ‘thrifty gene’. In light of this possible role, the endocannabinoid system can be considered a promising target for the pharmacological development in diabetes and complicated obesity. View study
09/28/2018
Author(s): V. Di Marzo. Endocannabinoids participate in the control of lipid and glycemic metabolism at several levels. View study
09/28/2018
Author(s): E. Appiah-Kusi1 , E. Leyden1 , S. Parmar1 , V. Mondelli2, P. McGuire1 and S. Bhattacharyya1. A study that summarizes the current evidence regarding alterations in the endocannabinoid system and its relationship in disorders such as schizophrenia. View study
09/28/2018
Author(s): Antonio Luchicchi & Marco Pistis. There is evidence suggesting that AEA and 2-AG possess specific pharmacological properties and that they also participate in different forms of synaptic plasticity and in different behavioral functions, such as learning and memory, reward and addiction, antinociception and anxiety. View study
09/28/2018
Author(s): Etienne Hebert-Chatelain 1,2, Leire Reguero 3, Nagore Puente 3, Beat Lutz 4 , Francis Chaouloff 1,2, Rodrigue Rossignol 2,5, Pier-Vincenzo Piazza 1,2 , Giovanni Benard 1,2, Pedro Grandes 3,6,Giovanni Marsicano 1,2,*,6. There is convergent anatomical and biochemical evidence that functional CB1 receptors are found in the mitochondria of the brain at low levels. With these data it is possible to conclude that there may be a direct relationship between the CB1 receptor and the mitochondrial functions in the brain and can be detected if certain experimental procedures are applied. View study
09/28/2018
Author(s): Simona Pisanti, Cristina Borselli, Olimpia Oliviero, Chiara Laezza, Patrizia Gazzero, and Maurizio Bifulco. Anandamide is potentially involved in the control of cancer growth directed both to the proliferation of tumor cells and to the angiogenic stimulation of the vasculature. View study
09/28/2018
Author(s): Maria Notarnicola, Caterina Messa, Antonella Orlando, Maurizio Bifulco, Chiara Laezza, Patrizia Gazzerro & Maria Gabriella Caruso. Cannabinoids have the ability to activate cannabinoid receptors CB1 and CB2. It is possible to control the proliferation of colon cancer by an additional mechanism of regulation by increasing the expression of CB1 by 17b-estradiol. View study
09/28/2018
Author(s): F. J. Bermúdez-Silva & J. Suárez & E. Baixeras & N. Cobo & D. Bautista & A. L. Cuesta-Muñoz & E. Fuentes & P. Juan-Pico & M. J. Castro & G. Milman & R. Mechoulam & A. Nadal & F. Rodríguez de Fonseca. The stimulation with CB1 was able to increase the secretion of insulin and glucagon, as well as the lipogenesis in the liver and adipose tissue, blocking the incorporation of glucose in the muscle cells, which led to a “saving cycle”: lower expenditure energy and greater energy storage. The improved release of insulin can help facilitate the incorporation of glucose into the adipocytes, while the improved release of glucagon can maintain high levels of plasma glucose, which favors this “saving cycle”. Under this hypothesis, CB1 can be considered a new ‘thrifty gene’. In light of this possible role, the endocannabinoid system can be considered a promising target for the pharmacological development in diabetes and complicated obesity. View study
09/28/2018
Author(s): Marta Rubio, Sara Valdeolivas, Fabiana Piscitelli, Roberta Verde, Valentina Satta, Eva Barroso, Marisol Montolio, Luis Miguel Aras, Vincenzo Di Marzo, Onintza Sagredo & Javier Fernandez-Ruiz. This study demonstrates that CBD or cannabidiol helps reduce seizures of childhood epilepsy, and dravets syndrome. View study
09/28/2018
Author(s): Nicholas A. Jones, Sarah E. Glyn, Satoshi Akiyama, Thomas D.M. Hill, Andrew J. Hill, Samantha E. Weston, Matthew D.A. Burnett, Yuki Yamasaki , Gary J. Stephens, Benjamin J. Whalley, Claire M. Williams. In this study, cannabidiol is evidenced as a strong candidate to treat human epilepsies, since it reduces the severity of seizures. View study
09/28/2018
Author(s): Mahshid Hosseinzadeh1 & Sara Nikseresht1 & Fariba Khodagholi 1,2 & Nima Naderi 1,3 & Nader Maghsoudi 1,2. In the chronic phase of epilepsy, post-treatment with cannabidiol could be considered as a protection mechanism of the temporal lobe, which improves the induction of the cellular autophagy pathway and antioxidant defense. View study
09/28/2018
Author(s): Naoki Amada, Yuki Yamasaki, Claire M. Williams and Benjamin J. Whalley. The anticonvulsant effects of cannabinoid cannabidivarin (CBDV) at the molecular level have been evaluated, confirming the behavioral effects on chemically induced seizures, highlighting their quality for clinical development. View study
09/28/2018
Author(s): TDM Hill, M-G Cascio, B Romano, M Duncan, R G Pertwee,C M Williams, B J Whalley and A J Hill. Botanical substances (BDS) derived from cannabis, rich in cannabidivarin (CBDV) and cannabidiol (CBD), showed anticonvulsant properties in three crisis models that were not mediated by the CB1 cannabinoid receptor. These findings support the clinical development of CBDV BDS for the treatment of epilepsy. View study
09/28/2018
Author(s): Robert E. Blair, Laxmikant S. Deshpande, Sompong Sombati, Katherine W. Falenski, Billy R. Martin, and Robert J. DeLorenzo. Cannabinoids have anticonvulsant properties, but their effects have not been evaluated in hippocampal neuronal culture models of acquired epilepsy (AD) and status epilepticus (SE). The results of this study represent powerful tools to investigate the molecular mechanisms that mediate the effects of cannabinoids on neuronal excitability. View study
09/28/2018
Author(s): Melisa J. Wallace, Jenny L. Wiley, Billy R. Martin, Robert J. DeLorenzo. It has been shown that cannabinoids are anticonvulsants in the maximum electroshock. This study establishes a role for the CB1 receptor in modulating convulsive activity in an animal model. View study
09/28/2018
Author(s): Nicholas A. Jones, Andrew J. Hill, Imogen Smith, Sarah A. Bevan, Claire M. Williams, Benjamin J. Whalley, and Gary J. Stephens. It is demonstrated that phytocannabinoids have important therapeutic properties, and specifically cannabidiol or CBD has anticonvulsant properties in animal models which highlights its potential as a new antiepileptic drug. View study
09/28/2018
Author(s): Elizabeth A Thiele, Eric D Marsh, Jacqueline A French, Maria Mazurkiewicz-Beldzinska, Selim R Benbadis, Charuta Joshi, Paul D Lyons, Adam Taylor, Claire Roberts, Kenneth Sommerville, on behalf of the GWPCARE Study Group. The Lennox-Gastaut syndrome is a severe form of epileptic encephalopathy resistant to conventional treatments. It has been shown that cannabidiol is effective for the treatment of patients with gout attacks associated with Lennox-Gastaut syndrome and is generally well tolerated. View study
09/28/2018
Author(s): Naoki Amada, Yuki Yamasaki, Claire M. Williams and Benjamin J. Whalley. The anticonvulsant effects of cannabinoid cannabidivarin (CBDV) at the molecular level have been evaluated, confirming the behavioral effects on chemically induced seizures, highlighting their quality for clinical development. View study
09/28/2018
Author(s): AJ Hill, MS Mercier, TDM Hill, SE Glyn, NA Jones,Y Yamasaki, T Futamura, M Duncan, CG Stott, GJ Stephens,CM Williams and BJ Whalley. The anticonvulsant profile of cannabidivarin CBDV is investigated for the first time in invitro and in vivo models, demonstrating that it is an effective anticonvulsant without significantly affecting normal motor function. View study
09/28/2018
Author(s): TDM Hill, M-G Cascio, B Romano, M Duncan, R G Pertwee,C M Williams, B J Whalley and A J Hill. Botanical substances (BDS) derived from cannabis, rich in cannabidivarin (CBDV) and cannabidiol (CBD), showed anticonvulsant properties in three crisis models that were not mediated by the CB1 cannabinoid receptor. These findings support the clinical development of CBDV BDS for the treatment of epilepsy. View study
09/28/2018
Author(s): Francis M. Filloux. Trials and controlled studies on the effects of cannabidiol in children with epilepsy have shown high quality medical evidence regarding its therapeutic benefits. View study
09/28/2018
Author(s): Daniel Friedman, M.D., and Orrin Devinsky, M.D. Studies in humans suggest that cannabidiol (CBD) and Δ9-THC may have beneficial properties for the treatment of epilepsy. However, these studies are quite limited and therefore it is not possible to draw conclusions about them. If randomized clinical trials show that specific cannabinoids are safe and effective, those preparations should be approved and made available. View study
09/28/2018
Author(s): Author: Benjamin J Whalley. Editors: Lyle Craker, Mahmoud A ElSohly, Aviva Romm, Ethan Russo, Roy Upton. Although cannabis and its components possess potentially beneficial properties for the treatment of epilepsy, the psychotropic effects of Δ9-THC limit or prohibit its generalized therapeutic use. If it is possible to confirm the anticonvulsant effects for crude non-psychoactive galenic preparations, it could offer an alternative to psychoactive cannabis preparations and standard medications. View study
09/28/2018
Author(s): Michal Tzadoka, Shimrit Uliel-Sibonib, Ilan Linderc, Uri Kramerb, Orna Epsteind,Shay Menascub, Andrea Nissenkorna, Omer Bar Yosefa, Eli Hymand, Dorit Granote, Michael Dorf, Tali Lerman-Sagiec, Bruria Ben-Zeev. A study was conducted with the objective of confirming the positive effects of medicinal cannabis enriched with cannabidiol (CBD) in children with epilepsy. As a result of this study, 89% of children reported a reduction in the frequency of seizures. However, 7% of patients reported aggravation of seizures that led to abstinence from CBD. In general, these results are very promising. It is necessary to perform more prospective and well designed clinical trials using medicinal cannabis enriched with CBD. View study